Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
Louisa Maria BulirschMarlene SaßmannshausenJennifer NadalRaffael LieglSarah ThieleFrank G HolzPublished in: The British journal of ophthalmology (2021)
The results of the SHIFT study indicate that switch to brolucizumab may represent a treatment option in patients with nAMD poorly responsive to other anti-VEGF agents. Further long-term analyses appear prudent to assess efficacy and safety of brolucizumab in a routine clinical setting.